Cassava Sciences’ on-going late stage trials for Alzheimer’s treatment gets DSMB nod

Posted on by wpadmin
Alzheimer"s disease - neurons with amyloid plaques

selvanegra/iStock via Getty Images

  • Cassava Sciences (NASDAQ:SAVA) announced the completion of a third interim safety review of simufilam in on-going late-stage trials Alzheimer’s patients.
  • The scheduled meeting of a Data and Safety Monitoring Board resulted in a recommendation that both of Cassava Sciences’ on-going Phase

Leave a Reply

Your email address will not be published. Required fields are marked *